Reading time is 3 mins
.
.
WORLD CANCER DAY WAS HELD ON FEBRUARY 4
Ankara Hematology and Oncology Association President Prof. Dr. said that 10 million people die from cancer every year in the world; it is estimated that deaths will increase to 13 million by 2030 if information, awareness and awareness are not increased.
Ankara Hematology and Oncology Association President Prof. Dr. spoke at the press conference held as part of the Ankara Hematology and Oncology Days, which was held for the second time this year due to the World Cancer Day on February 4, 2022.
.
20 MILLION PEOPLE ARE DIAGNOSED WITH IT EVERY YEAR
Prof. Dr. stated that 20 million people are diagnosed with cancer every year and that 10 million people die due to cancer; it is estimated that cancer deaths will increase to 13 million by 2030 if information awareness and awareness are not increased.
.
TURKISH PROFESSOR DREW ATTENTION TO EARLY DIAGNOSIS
Prof. Dr. stressed that cancer is a preventable disease, noting that cancer can be diagnosed early, so screening should be done at certain periods in screening centers.
Prof. Dr. “One thousand 500-2 thousand new cases of leukemia are observed in our country every year. Although the incidence of leukemia has increased, with current treatments, long-term life has increased by up to 60 percent. In some childhood leukemias, this rate reaches up to 90 percent. A stem cell is a type of stem cell. But for those who do not have a suitable transmitter, it is also not the end of life. A life without leukemia is also possible with new treatments. Leukemia treatment is a high, costly and laborious process. However, patients and relatives of patients in our country should know that any drug that has been approved for use in America and Europe can also be accessed in Turkey,” he said.
.
UP TO 95 PERCENT SUCCESS IS POSSIBLE IN LYMPH NODE CANCER
Prof. Dr. said that lymphoma is a cancer of the lymphatic system, up to 95 percent success in lymph node cancers is possible, regular between and adequate doses of medication prolong life.
Prof. Dr. “One of the most important indicators for life expectancy in the treatment of lymphoma is the total dose of drugs taken by the patient in the first months. In this regard, it is necessary to take a sufficient dose of the drug. For this reason, it should not delay the treatment periods between at intervals of two or three weeks unless there is a medical necessity. ‘Multiple myeloma’ is a type of bone marrow cancer. The incidence varies from 3 to 9 per 100 thousand per decum. The incidence increases with age. The success rates of new generation drugs and autologous stem cell transplantation in patients with multiple myeloma have increased significantly in recent years. All kinds of medicines, treatment and care of patients with myeloma in our country are offered in our cancer centers at the standards of developed world countries,” he said.
.
50 PERCENT CAN BE TREATED WITH STANDARD TREATMENT METHODS
Prof. Dr. noted that personalized treatments account for 73 percent of cancer drugs under development, and said;
– Targeted therapies significantly increase survival rates. In most types of cancer, chemotherapy are between 30-50 percent, while treatment-related response rates with targeted treatments specific to the person are up to 80 percent.
– The future focuses on the immune system, stem cells, cells, and genetic basis. Because, even among patients with the same type of disease, significant differences can be observed in terms of clinical course, response to treatment, and the quality of response.
– Turkey has the best Hematology and Oncology clinical research infrastructure. We are more advanced than the European Union countries in terms of legal infrastructure. Currently, more than 50 percent of cancer patients are treatable with standard methods.
.
.
.
.
Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.
Physician's Resume:
Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.
Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.
In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.
Awards:
Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.
Certificates:
Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .
Professional Members:
American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.
Disclaimer:
Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.